Somatostatin receptors and regulation of cell proliferation

Digestive and Liver Disease

Volumn 36, Issue SUPPL. 1, 2004, Pages

  Bousquet, C ^a   Guillermet, J ^a   Vernejoul, F ^a   Lahlou, H ^a   Buscail, L ^a   Susini, C ^a  

^a CHU RANGUEIL   (France)

Author keywords

Antioncogene; Apoptosis; Inhibition; Proliferation; Receptors; Somatostatin; sst2

Indexed keywords

G PROTEIN COUPLED RECEPTOR; NEUROPEPTIDE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; TAMOXIFEN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; SACCHAROMYCES CEREVISIAE PROTEIN; SST2 PROTEIN, S CEREVISIAE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOID; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; COGNITION; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; EXOCRINE SECRETION; GASTROINTESTINAL ABSORPTION; GLIOMA; GROWTH INHIBITION; HORMONE RELEASE; HUMAN; INHIBITION KINETICS; INTESTINE MOTILITY; KAPOSI SARCOMA; MENINGIOMA; METASTASIS INHIBITION; MITOSIS INHIBITION; MOLECULAR MECHANICS; MOTOR PERFORMANCE; MOUSE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; NUTRIENT UPTAKE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; RAT; RECEPTOR UPREGULATION; REVIEW; TUMOR CELL; TUMOR VASCULARIZATION; VASOCONSTRICTION; CELL DIVISION; PHYSIOLOGY;

CELL DIVISION; GTPASE-ACTIVATING PROTEINS; RECEPTORS, SOMATOSTATIN; SACCHAROMYCES CEREVISIAE PROTEINS; SOMATOSTATIN;

EID: 2442676755     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2003.11.007     Document Type: Article

References (61)

1. Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 1994;8:25-44.
2. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98.
3. Meyerhof W. The elucidation of somatostatin receptor functions: a current view. Rev Physiol Biochem Pharmacol 1998;133:55-108.
4. Kreienkamp HJ, Honck HH, Richter D. Coupling of rat somatostatin receptor subtypes to a G-protein gated inwardly rectifying potassium channel (GIRK1). FEES Lett 1997;419:92-4.
5. 2+ current in the pituitary cell line AtT-20. Neuroscience 1996;71:1073-81.
6. 2+ currents in rat insulinoma 1046-38 cells. FEBS Lett 1998;425:137-40.
7. Le Romancer M, Cherifi Y, Levasseur S, Laigneau JP, Peranzi G, Jais P, et al. Messenger RNA expression of somatostatin receptor subtypes in human and rat gastric mucosae. Life Sci 1996;58:1091-8.
8. Renstrom E, Ding WG, Bokvist K, Rorsman P. Neurotransmitter-induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin. Neuron 1996;17:513-22.
9. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994;91:2315-9.
10. Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol 1997;11:1062-9.
11. Florio T, Rim C, Hershberger RE, Loda M, Stork PJ. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol Endocrinol 1994;8:1289-97.
12. Florio T, Yao H, Carey KD, Dillon TJ, Stork PJ. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol 1999;13:24-37.
13. Bito H, Mori M, Sakanaka C, Takano T, Honda Z, Gotoh Y, et al. Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade. J Biol Chem 1994;269:12722-30.
14. Lahlou H, Saint-Laurent N, Esteve J. SST2 somatostatin receptor mediates cell cycle arrest through Ras- and Rap1-mediated ERK activation and p27Kip1 up-regulation. Biol Cell 2001;93:107.
15. Sellers LA, Feniuk W, Humphrey PP, Lauder H. Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation. J Biol Chem 1999;274:16423-30.
16. Cordelier P, Esteve JP, Bousquet C, Delesque N, O'Carroll AM, Schally AV, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci USA 1997;94:9343-8.
17. Hou C, Gilbert RL, Barber DL. Subtype-specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2. J Biol Chem 1994;269:10357-62.
18. Buchan AM, Lin CY, Choi J, Barber DL. Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibres, and cell migration. J Biol Chem 2002;277:28431-8.
19. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248-91.
20. Weckbecker G, Raulf F, Stolz B, Brans C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993;60:245-64.
21. Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, et al. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors [in process citation]. J Endocrinol Invest 1998;21:512-9.
22. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-8.
23. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998;282:737-40.
24. Canobbio L, Cannata D, Miglietta L, Boccardo F. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res 1995;15:2687-90.
25. Martinez V, Curi AP, Torkian B, Schaeffer JM, Wilkinson HA, Walsh JH, et al. High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice. Gastroenterology 1998;114:1125-32.
26. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drags 1997;15:77-86.
27. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
28. Watson JC, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001;85:266-72.
29. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-43.
30. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001;92:545-50.
31. Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A, et al. Somatostatin controls Kaposi's sarcoma tumour growth through inhibition of angiogenesis. FASEB J 1999;13:647-55.
32. Patel YC. Molecular pharmacology of somatostatin receptor subtypes 1997;20:348-67.
33. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumours using in situ hybridization. Cancer Res 1994;54:3455-9.
34. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumours. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440:461-75.
35. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumours of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 2000;85:3882-91.
36. Dutour A, Kumar U, Panetta R, Panetta R, Ouafik L, Fina F, et al. Expression of somatostatin receptor subtypes in human brain tumours. Int J Cancer 1998;76:620-7.
37. Hofland LJ, Liu Q, Van Koetsveld PM, Zuijderwijk J, Van Der Ham F, De Krijger RR, et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor-positive tumours. J Clin Endocrinol Metab 1999;84:775-80.
38. Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies [in process citation]. Clin Cancer Res 1998;4:2047-52.
39. Oomen SP, Hofland LJ, van Hagen PM, Lamberts SW, Touw IP. Somatostatin receptors in the haematopoietic system. Eur J Endocrinol 2000;143:89-14.
40. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000;85:2564-71.
41. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxford) 2001;54:641-9.
42. Schulz S, Schmitt J, Quednow C, Roessner A, Weise W. Immunohistochemical detection of somatostatin receptors in human ovarian tumours. Gynecol Oncol 2002;84:235-40.
43. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823-7.
44. Pinzani P, Orlando C, Raggi CC, Distante V, Valanzano R, Tricarico C, et al. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology. Regul Pept 2001;99:79-86.
45. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217:143-52.
46. Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol 1999;13:82-90.
47. Alderton F, Fan TP, Schindler M, Humphrey PP. Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation. Br J Pharmacol 1998;125:1630-3.
48. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995;92:1580-4.
49. Bousquet C, Delesque N, Lopez F, Saint-Laurent N, Esteve JP, Bedecs K, et al. sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase Shp-1. J Biol Chem 1998;273:7099-106.
50. Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of Shp-1. J Biol Chem 1999;274:15186-93.
51. Alderton F, Humphrey PP, Sellers LA. High-intensity p38 kinase activity is critical for p21(cip1) induction and the antiproliferative function of G(i) protein-coupled receptors. Mol Pharmacol 2001;59:1119-28.
52. Held-Feindt J, Forstreuter F, Pufe T, Mentlein R. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res Mol Brain Res 2001;87:12-21.
53. Cattaneo MG, Taylor JE, Culler MD, Nisoli E, Vicentini LM. Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett 2000;481:271-6.
54. Liu D, Martino G, Thangaraju M, Sharma M, Halwani F, Shen SH, et al. Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced apoptosis. J Biol Chem 2000;275:9244-50.
55. Sharma K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998;76:259-66.
56. Teijeiro R, Rios R, Costoya JA, Castro R, Bello JL, Devesa J, et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 2002;12:31-8.
57. Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 2003;100:155-60.
58. Delesque N, Buscail L, Esteve JP, Saint-Laurent N, Muller C, Weckbecker G, et al. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997;57:956-62.
59. Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N, et al. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer [see comments]. Hum Gene Ther 1999;10:995-1008.
60. Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000;97:9180-5.
61. Vernejoul F, Faure P, Benali N, Cause D, Tiraby G, Pradayrol L, et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 2002;62:6124-31.